Should I Buy CSBR? CSBR 2026 Analysis

Should You Buy Champions Oncology Inc (CSBR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

6.550

1 Day change

0.31%

52 Week Range

11.980

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: price is trading below key levels (below S1 6.761 and well below pivot 7.177) while momentum is weakening.
Near-term pattern-based outlook is biased down (estimated -0.75% next day, -1.83% next week), which argues against chasing an entry today.
Fundamentals are mixed: revenue is growing, but profitability and EPS fell sharply YoY in the latest quarter (2026/Q2), reducing the appeal of buying into current technical weakness.
Best stance today: avoid/new money stay out; if already holding, consider trimming until the stock reclaims 6.76–7.18 with improving momentum.

Technical Analysis

Trend/MAs: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests a longer-term uptrend, but price action is currently weak versus nearby levels.
Momentum: MACD histogram -0.00384 (below 0 and negatively expanding) = downside momentum building.
RSI: RSI(6) 48.553 (neutral) = no oversold bounce signal.
Key levels: Support S2 6.504 then S1 6.761 (currently below S1); resistance pivot 7.177 then R1 7.594.
Quant/pattern read-through: Similar-pattern analysis implies a higher probability of mild downside over the next day/week/month.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Extremely call-skewed open interest (put/call OI ratio 0.03; calls 138 vs puts 4), but this is on very small absolute open interest.
Activity: Options volume is effectively zero today (call vol 0, put vol 0), so sentiment from traded flow is not informative.
Volatility: 30D IV ~193.73 vs historical vol ~63.73 = options priced very rich, but IV percentile 17.6 / IV rank ~22.99 suggests IV has been higher recently (i.e., IV has cooled from elevated levels).

Technical Summary

Sell

Buy

Positive Catalysts

- No negative headlines in the last week (news feed shows none), reducing immediate headline risk.
- Gross margin improved materially YoY (51.7%, +15.07% YoY) in 2026/Q2, which can become a tailwind if operating leverage returns.
- Call-heavy open interest could amplify upside if the stock reclaims the pivot and shorts/weak hands are forced to cover (though the option market is illiquid).

Neutral/Negative Catalysts

- Weakening momentum (MACD negative and expanding) while trading below S1 increases the odds of a drift toward S2 (6.504).
- Pattern-based forecast skews negative over the next day/week.
- Options are extremely illiquid today (0 volume), limiting the usefulness of options sentiment and increasing gap risk.
- Trading trends: Hedge funds neutral and insiders neutral (no supportive accumulation signal).
- No recent event-driven catalysts (no news in the last week) to reverse the current soft tape.

Financial Performance

Latest quarter: 2026/Q2.
Revenue: 15.035M, +11.46% YoY (healthy top-line growth).
Profitability: Net income 0.268M, -63.19% YoY (meaningful deterioration).
EPS: 0.02, -60.00% YoY (earnings power down despite revenue growth).
Gross margin: 51.7%, +15.07% YoY (strong improvement, but not yet translating into bottom-line growth).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target updates were provided in the dataset, so there is no observable recent trend in upgrades/downgrades or target changes.
Wall Street-style pros view (inferred from provided fundamentals): accelerating revenue and improved gross margin.
Wall Street-style cons view (inferred): sharp YoY decline in net income/EPS and currently weakening technicals; limited sentiment signal due to sparse coverage/data.
Influential/political activity: No recent congress trading data available; no politician/influential-figure transactions were provided.

1 Analyst Rating

Wall Street analysts forecast CSBR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSBR is 12 USD with a low forecast of 12 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 6.530

Low

Averages

High

Current: 6.530

Low

Averages

High

Craig-Hallum

Matt Hewitt

Strong Buy

Maintains

$8 → $12

AI Analysis

2025-03-12

Reason

Craig-Hallum

Matt Hewitt

Price Target

$8 → $12

AI Analysis

2025-03-12

Maintains

Strong Buy

Reason

Craig-Hallum analyst Matt Hewitt raised the firm's price target on Champions Oncology to $12 from $8 and keeps a Buy rating on the shares. The firm notes the company reported strong Q3 results, which featured a substantial data licensing deal signed by a large pharma company for rights to their cancer data. The company recognized $4.5M for this with potential of up to $8M. This deal led to revenues of $17M vs. $12.9M estimates and led to beats across the board. Craig-Hallum sees this company capitalizing on its large data offerings as it seeks to make drug development more efficient for customers.

CSBR Should I Buy

CSBR Should I Buy

Should You Buy Champions Oncology Inc (CSBR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch